Diffuse large B-cell lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 42
• CD20 22
• BCL-2 13
• MYC 10
• PD-1 12
• BTK 10
• TP53 7
• PD-L1 3
• CD22 7
• STAT3 0
• CD30 5
• CD47 0
• PI3K 0
• EZH2 1
• LAG-3 0
• ALK 0
• CTNNB1 0
• JAK 0
• STING 0
• BCMA 2
• EGFR 0
• METTL3 0
• mTOR 0
• AKT 0
• CD38 0
• IL-6 0
• JNK 0
• MMP-9 0
• PKM2 0
• PRMT5 0
• TIGIT 1
• TIM-3 0
• ABL1 0
• ARID1A 1
• ATM 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD40 0
• CDKN2A 0
• CTLA-4 0
• CXCR4 0
• FGFR 0
• FTO 0
• GPX4 0
• HDAC 0
• IL-1 0
• IL-15 0
• MYCN 0
• NLRP3 0
• NOTCH1 1
• PARP 0
• PINK1 0
• PPAR 0
• RAS 0
• SHP2 0
• SIRT1 0
• TERT 0
• TFEB 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 36+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Updated 14 Jul 2026

  “This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  NCT06649812· National Cancer Institute (NCI)· Source

• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

  NCT04799275· National Cancer Institute (NCI)· Source

• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

  NCT03984448· National Cancer Institute (NCI)· Source

• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Hoffmann-La Roche· Source

• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589· BeOne Medicines· Source

• Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

  NCT05583149· Patrick C. Johnson, MD· Source

• HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements

  NCT03620578· Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 49
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 4
• Flow Cytometry 7
• Immunohistochemistry 36
• Liquid Biopsy 1
• Circulating Tumor DNA 12
• Xenograft Model Antitumor Assays 30
• Positron-Emission Tomography 15
• Magnetic Resonance Imaging 28
• Machine Learning 11
• Deep Learning 9
• Cohort Studies 15
• Genome-Wide Association Study 4

See which targets of this disease your abstract mentions, and go to the people working on them.